Frederic Ors

Dartmouth, Nova Scotia, Canada
Fred has served as our Chief Executive Officer since April 2016. As CEO, he has led the transformation of IMV into a leading clinical-stage immune oncology company with world-class collaborators and a strong scientific foundation.
He has more than 20 years of experience in the biopharmaceutical industry, having served in a number of management roles encompassing business development, intellectual property, strategic planning, pre-marketing and communication. Before joining IMV, Fred spent 14 years at Medicago serving in many roles of increasing responsibility, most recently as Vice President of Business Development and Strategic Planning. He had been an integral part of Medicago’s success, including securing more than $300M CAN in non-dilutive funding in revenues and future milestones from licensing agreements and government contracts, and the $357M CAN deal acquisition by Mitsubishi Pharma in 2013. Fred served as second Vice-Chair of the Vaccine Industry Committee of Biotech Canada b
Speaking In
2:00 PM - 2:15 PM
Wednesday, October 23
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more…